Rhinitis Alergi Kelompok 1

8/16/2019 Rhinitis Alergi Kelompok 1

1/46

RHINITIS ALERGI


2/46

KELOMPOK 1• AYU APRILIANI 260110140078

• PUTRI RARASWATI 260110140079

• UMMI HABIBAH 260110140080

• AYYU WIDYAZMARA 260110140081

• ANGGIA DIANI A. 260110140082

• SITI NURROHMAH 26011014008

• AI SITI RIKA !. 260110140084

• NISA MAULANI N. 26011014008"

• TI!!ANY SABILLA R. 260110140086

• NURMALIA SARASWATI 260110140087

• MILA TRI #AHYANI 260110140088• SITI ROSITAH 260110140089

• ADAM RENALDI 260110140090

• HOTMA GURNING W. 260110140092


3/46

KASUS

S$%&'() *'+',-,' /$&('*' ,&. /$&3,-' 20 '+3( ''() 5$

'%$5 3(35 *$*/$- %/' 5'&$(' +-3()(' /$&'-&*$$&:*$$&.

D$''( *-())3 $&'5+-& -' *$&',' 5$''(' /$&' '( -'

*$()%/'-(' $()'( ,$*&% +-3() ;-


4/46

PENYAKIT APA YANG

SEBENARNYA DIDERITA OLEHSAUDARA J???


5/46

RHINITIS ALERGI


6/46

DE!INISI

R-(--, '$&)- '''+ $('5- -(>'*',- '() -,$/'/5'( %$+

&$'5,- '$&)- '' ',-$( '%- '() ,$/$3*(' ,3'+

$&,$(,--,',- $()'( '$&)$( '() ,'*' ,$&' -$',5'(('

,3'3 *$-'%& 5-*-' 5$-5' $&?'- ''&'( 3'()'( $()'(

'$&)$( ,$,->-5 $&,$/3 @;%( P-&3$ 1986.

M$(3&3 WHO ARIA @ Allergic Rhinitis and its Impact on

Asthma &-(--, '$&)- '''+ 5$'-('( '' +-3() $()'(

)$?'' /$&,-(:/$&,-( &-(%&$ &',' )'' '( $&,3*/' ,$$'+

*35%,' +-3() $&''& '$&)$( '() -$&'('&'- %$+ I)E.


7/46


8/46

ANATOMI DAN !ISIOLOGI


9/46

ANATOMI DAN !ISIOLOGI


10/46

PATO!ISIOLOGI


11/46

PATO!ISIOLOGI

• R-(--, '$&)- *$&3'5'( ,3'3 $('5- -(>'*',- '()

-''- $()'( '+' sensitisasi '( --53- $()'(

reaksi alergi.

• R$'5,- '$&)- $&-&- '&- 2 >',$ '-3

1. immediate phase allergic reaction ''3 &$'5,- '$&)-

>',$ ceat @RA!# '() /$&'(),3() ,$?'5 5%('5

$()'( '$&)$( ,'*'- 1 ?'* ,$$'+('

2. late phase allergic reaction ''3 &$'5,- '$&)- >',$

la!"at @RA!L '() /$&'(),3() 2:4 ?'* $()'(

3(',$ +-$&&$'5-C-', ,$$'+

$*''&'( '( '' /$&'(),3() 24:48 ?'*.


12/46

PATO!ISIOLOGI

• '+' ,$(,--,',-

A(-)$( P&$,$(-() #$AP# '5'( *$('()5' '$&)$(

'() *$($*$ - $&*35''( *35%,' +-3() '()

5$*3-'( -&$,$(',-5'( '' ,$ T +$$& @T+0

AP# *$$', ,-%5-( ,$$&- -($&$35-( 1 @IL:1 '()

'5'( *$()'5->5'( T+0 3(35 /$&&%->$&',- *$(?'- T+1

'( T+2. T+2 '5'( *$()+',-5'( /$&/')'- ,-%5-(

,$$&- IL: IL:4 IL:" '( IL:1.

IL:4 '( IL:1 '' --5' $&*35''( ,$ -*>%,- B '5->*$*&%35,- -*3(%)%/3-( E @I)E.


13/46

PATO!ISIOLOGI

• R$'5,- A$&)- !',$ #$' @RA!#.

• ke#$a rantai IgE akan !engikat alergensesi%ik #an ter&a#i #egran$lasi

'eca(n)a #in#ing sel* !ast+sit #an

"as+%il !e#iat+r ki!ia leas

ter$ta!a (ista!in,


14/46


15/46


16/46

GEALA KHUSUS• B$&','&5'( ,->' /$&'(),3()('

1. I($&*-$( @5''():5''() /-' )$?'' 53&'() '&- 4

+'&-*-())3 ''3 53&'() '&- 4 *-())3.

2. P$&,-,$(*$($' /-' )$?'' $/-+ '&- 4 +'&-*-())3 '(

''3 $/-+ '&- 4 *-())3.

B$&','&5'( -()5' /$&' &-()'((' $('5- &-(--, '$&)- -/')-*$(?'-

1. R-()'( /-' -'5 -$*35'( )'())3'( -3& )'())3'( '5->-',

+'&-'( /$&,'('- /$&%'+&')'/$'?'& /$5$&?' '( +'

:+' '-( '() *$())'())3.

2. S$'() ''3 /$&' /-' $&'' ,'3 ''3 $/-+ '&- )'())3'($&,$/3

-'',


17/46

!AKTOR RESIKO


18/46

BIOKIMIA KLINIK


19/46


20/46


21/46


22/46

TERAPI SINTESIS


23/46

TERAPI SINTESIS

O/' %/' '() -)3('5'(

1. A(-+-,'*-(• A(')%(-, &$,$%& +-,'*-( H1 /$&-5''( $()'( &$,$%&

H1 '(' *$()'5-C',- &$,$%& '() *$( $&->$&

@'(-+-,'*-( (%(,$',-

• A(-+-,'*-( *$()'(')%(-, $&*$'/--', 5'-$&

$*/$(35'( /$()5'5 '( &',' '(', ,$&' )''.


24/46

TERAPI SINTESIS


25/46


26/46


27/46


28/46

TERAPI SINTESIS

• D%,-, O&' '(-+-,'*-( '( $5%()$,'( '() 3*3* -)3('5'(


29/46

TERAPI SINTESIS

. K%&-5%,$&%- N','

E>$5 3'*' '' *35%,' +-3()

•F *$()3&'()- -(>'*',- $()'( *$*/%5$$','( *$-'%&

•F *$($5'( 5$*%'5,-, ($3&%>-

•F *$()3&'()- $$*' -(&',$

•F *$($/'/5'( C',%5%(,&-5,- &-()'( '(

•F *$()+'*/' &$'5,- >',$ '*/' '() -$&'('&'- %$+ ,$*',


30/46


31/46


32/46


33/46


34/46

TERAPI SINTESIS

6. M%($35',• A(')%(-, &$,$%& $35%&-$( 3(35 $('()'('( &-(--, '$&)-

*3,-*'(.

•E>$5-> 5$-5' -/$&-5'( 3())' ''3 ''* 5%*/-(',- $()'(

'(-+-,'*-(

•D%,-, $',' '( &$*'?' 10 *)'/$ $& +'&-. A('5 '('5 @6:14

'+3( ,'3 '/$ 53('+ " *) $&+'&-

•O/' -(- +'&3, -/$&-5'( '' ,%&$ +'&- ?-5' ',-$( *$($&-'

5%*/-(',- ',*' '( &-(--, '$&)-5 *3,-*'(.

• A$&('-C$ $&'- /'&3 ('*3( -'5 $/-+ $>$5-> -/'(-()5'(

'(-+-,'*-( ,$$5-> $&->$& '( $/-+ 53&'() $>$5-> '&-''

5%&-5%,$&%- -(&'(','.


35/46

TERAPI SINTESIS

• R-'' P$())3(''( O/'

1.S$*&% +-3() ;-$.S'/3'*% I(+'$&

4.B$


36/46


37/46

TERAPI SINTESIS

2. T'/$ S3'>$T'/$ S3'>$ *$()'(3() P,$3%$>$&-( H# 60 *)

I(-5',- G$?'' 5%()$,- (',' ,$$&- '' ,-(3,--,.

ESO I(,%*(-'

D%,-, D$',' '( '('5 -'', 12 '+3( ,$+'&- 5'- ,'3

'/$. @IS!I 2011: 2012.

M$5'(-,*$ %/' ,-*'%*-*$-5 '() /$5$&?' $()'(


38/46


39/46


40/46


41/46

• N-'%3-: D'3( M$'$3


42/46

TERAPI NON!ARMAKOLOGI

M%->-5',- )'' +-3 $()'(


43/46

MONITORING


44/46

MONITORING

Environmental control

Drug Selection

Drug Selection

Adherent Assessment

Adjust dosage OR

Switch drug

Consideration for

Montelukast OR

Immunotheraph


45/46


46/46

Rhinitis Alergi Kelompok 1

Documents